ABSTRACT

Fungi that cause human illness are spreading rapidly, posing a serious public health threat. Primary fungi and opportunistic fungi are two types of medically important fungi. Unfortunately, they are frequently discovered late, when treatment efficacy is limited, sometimes less than 50%, and the cost of lost lives, length of hospital stay, and overall healthcare costs is significantly raised. Early treatment are vital for achieving a better result, which is defined as a lower rate of morbidity and mortality. This problem has also been exacerbated by HIV and other disorders that produce immunosuppression. The epidermis, keratinous tissues, and mucous membranes are all affected by superficial and subcutaneous fungal infections. Some of the most common skin illnesses, which impact millions of people across the world, are included in this category. Candida albicans and Aspergillus spp. are the most commonly seen pathogens, however non-albicans Candida spp. are becoming increasingly relevant. This study discusses the indications for using currently available antifungal drugs, as well as their side effects, drug interactions, dosing ease, the application in individuals with well before disease states. Keywords: Antifungal agents, Candida, Aspergillus, Mycosis
Publication date: 01/12/2022

https://ijbpas.com/pdf/2022/December/MS_IJBPAS_2022_6682.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.12.6682